Product Information PI - Roche Australia
Product Information PI - Roche Australia
Product Information PI - Roche Australia
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Table 3:<br />
Summary of Secondary Efficacy Results (Median and 95% Confidence Interval)<br />
from the Studies in the Treatment of Naturally Acquired Influenza<br />
Study (Protocol<br />
Number(s))<br />
Treatment group<br />
Study WV15671<br />
• Placebo<br />
(n = 129)<br />
• TAMIFLU<br />
75 mg twice daily<br />
(n = 124)<br />
AUC of total<br />
symptom<br />
score<br />
(h)<br />
Time to<br />
become afebrile<br />
(h)<br />
962.6 # 64.6<br />
(59.2 - 76.3)<br />
597.1 # 41.5<br />
(34.0 - 48.0)<br />
AUC of virus<br />
titer<br />
(log 10 TCID 50 .h/<br />
mL)<br />
Duration of virus<br />
shedding<br />
(h)<br />
126.7 # 70.2<br />
(68.0 - 71.4)<br />
111.4 # 66.8<br />
(64.6 - 68.8)<br />
p-value*